FDA监管成分
该成分是FDA批准或监管的。未经有效处方购买可能违反联邦法律。请在您所在地区核实所有法律规定。
Dulaglutide
Trulicity
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.
作用机制
GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.
研究协议
仅供研究使用,非医疗建议。
Research protocols use 0.75mg weekly, escalating to 1.5mg weekly after 4 weeks. Maximum studied dose is 4.5mg weekly.
研究笔记
Clinical Research Status
Dulaglutide received FDA approval in 2014 for type 2 diabetes and has been studied in the extensive AWARD clinical trial program spanning multiple comparator studies. The REWIND cardiovascular outcomes trial demonstrated a 12% reduction in MACE in a broad population including primary prevention patients. It is not currently approved for weight management as a standalone indication.
Key Published Findings
The AWARD trials showed HbA1c reductions of 0.8-1.6% depending on comparator and population studied. REWIND was notable for enrolling a majority of patients without established cardiovascular disease, demonstrating broader preventive benefit. Weight loss in diabetes trials averaged 1.5-3 kg, modest compared to newer GLP-1 agonists optimized for obesity.
Safety Profile
Gastrointestinal adverse events (nausea, diarrhea, vomiting) are the most common side effects, occurring in 15-25% of patients during titration. The same class-wide MTC boxed warning applies, based on rodent thyroid C-cell tumor findings. Injection site reactions are generally mild, and the pre-filled pen device has high patient satisfaction scores.
Comparison to Related Compounds
Compared to semaglutide, dulaglutide produces less weight loss and slightly less HbA1c reduction but uses a simpler auto-injector device that some patients prefer. Its large molecular size (approximately 63 kDa) prevents oral bioavailability, unlike semaglutide which has an oral formulation. Relative to liraglutide, the weekly dosing of dulaglutide offers significant convenience advantage with comparable efficacy.
Community Observations
Trulicity's pen device is frequently cited as one of the most user-friendly among injectable GLP-1 agonists, requiring no needle handling. Patients transitioning from dulaglutide to semaglutide for greater weight loss often report stronger GI side effects initially. Some endocrinologists continue prescribing dulaglutide for patients who prioritize injection simplicity and have modest weight loss goals.
半衰期
~5 days
复溶
Pre-filled pen (no reconstitution)
存储
冻干
Refrigerate 2-8C. Do not freeze.
复溶后
Room temperature up to 14 days if needed.
美国法律状态
又称作
最新研究
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
Highlighting the safety and potential benefits of GLP-1 receptor agonists in managing type 2 diabetes patients with or at risk for acute pancreatitis.
常见问题
什么是 Dulaglutide?
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.
Dulaglutide 如何起作用?
GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.
Dulaglutide 在美国的监管状态是什么?
FDA-approved (Rx only)
Dulaglutide 的半衰期是多少?
~5 days
Dulaglutide 还有哪些名称?
Trulicity
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明